# Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia

> **NCT06263881** · PHASE3 · COMPLETED · sponsor: **Materia Medica Holding** · enrollment: 370 (actual)

## Conditions studied

- Community-acquired Pneumonia
- Pneumonia

## Interventions

- **DRUG:** Raphamin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06263881
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2025-03-19
- **Final completion:** 2025-03-19
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263881, "Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06263881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*